Oral L-Glutamine as A Shield Against Chemotherapy Induced Mucositis: Evidence from A Cross-Sectional Study

Background: Chemotherapy-induced mucositis (CIM) is a notable side effect of cancer therapy, causing painful sores and inflammation throughout the digestive system.L-glutamine, a conditionally essential amino acid, has demonstrated promise in alleviating CIM by supporting mucosal healing and immune function.Nevertheless, ensuring patients consistently take glutamine supplements remains problematic.Purpose: This research assesses the efficacy of L-glutamine in CIM prevention and investigates its association with mucositis severity and patient compliance. Methodology:A six-month cross-sectional study was performed at a tertiary healthcare facility.The study included 104 CIMdiagnosed patients.Information was gathered through direct questioning and examined using descriptive statistics and Chi-square test.Mucositis severity was classified using the CTCAE scale, and adherence to glutamine supplementation was evaluated.Results: Compliant patients did not experience severe mucositis (grade 3/4), while 63% of non-compliant patients developed grade 3 or 4 mucositis (p < 0.05).Non-adherence, observed in patients, was primarily due to expense and palpability issues.Glutamine significantly decreased the occurrence of severe CIM (p < 0.0001).Mucositis was most frequently observed in the mouth (31%) and intestines (26%). Conclusion:L-glutamine effectively prevents severe CIM, highlighting its importance as a supportive treatment.Initiatives to enhance adherence, such as reducing costs and educating patients, are essential for improving outcomes.Additional studies are necessary to determine long-term benefits and develop strategies to increase compliance.